CRVS
vs
S&P 500
CRVS
S&P 500
Over the past 12 months, CRVS has significantly outperformed S&P 500, delivering a return of +283% compared to the S&P 500's +13% growth.
Stocks Performance
CRVS vs S&P 500
Performance Gap
CRVS vs S&P 500
Performance By Year
CRVS vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Corvus Pharmaceuticals Inc
Glance View
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The company is headquartered in Burlingame, California and currently employs 28 full-time employees. The company went IPO on 2016-03-23. The firm develops drugs and antibodies that target the critical cellular elements of the immune system. The firm's lead product candidate is CPI-006, a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its next product candidate, CPI-818, is a selective, covalent inhibitor of ITK. CPI-818 is designed to inhibit the proliferation of certain malignant T-cells. Its third product candidate, Ciforadenant is an oral, small molecule antagonist of the A2A receptor for adenosine. Its product candidate pipeline includes CPI-006, B-Cell Activating anti-CD73 antibody; CPI-818, ITK Inhibitor, Ciforadenant Adenosine A2A Receptor Antagonist; CPI-182, Anti-CXCR2 Antibody designed to block inflammation and Myeloid Suppression, and CPI-935, Adenosine A2B Receptor Antagonist.
